Satish Patel

Satish Patel

Auto-generated profile, based on publicly available information

Satish Patel

Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SPSatish Patel
Satish Patel
WYWei Yang
Wei Yang
KKKristina Kozusko
Kristina Kozusko
VSVladimir Saudek
Vladimir Saudek
DSDavid B. Savage
David B. Savage
Significance: Lipolysis refers to the hydrolysis of triacylglycerol stored within lipid droplets. It is an essential step in the catabolism of triacylglycerol in all cells. Within adipocytes, the regulation is highly dynamic, whereas in other cell types basal lipolytic flux is less effectively suppressed and lipolysis is not as dramatically stimulated. These differences reflect the obviously different functions of adipose tissue, the body’s principle energy store, compared with other sites such as the liver or skeletal muscle, where lipids may be exported within lipoproteins or oxidized. Our data suggest that the molecular differences between perilipins1, 2, and 3 can largely account for these functional differences and thus provide a plausible hypothesis for their preservation in evolution.

2 September 2022 in Molecular Metabolism
Verified
Journal Article
Open access
SPSatish Patel
Satish Patel
AHAfreen Haider
Afreen Haider
AAAnna Alvarez-Guaita
Anna Alvarez-Guaita
GBGuillaume Bidault
Guillaume Bidault
JMJulia Sarah El-Sayed Moustafa
Julia Sarah El-Sayed Moustafa
DSDavid B. Savage
David B. Savage
Obesity in humans and mice is associated with elevated levels of two hormones responsive to cellular stress, namely GDF15 and FGF21. Over-expression of each of these is associated with weight loss and beneficial metabolic changes but where they are secreted from and what they are required for physiologically in the context of overfeeding remains unclear. Here we used tissue selective knockout mouse models and human transcriptomics to determine the source of circulating GDF15 in obesity. We then generated and characterized the metabolic phenotypes of GDF15/FGF21 double knockout mice. Circulating GDF15 and FGF21 are both largely derived from the liver, rather than adipose tissue or skeletal muscle, in obese states. Combined whole body deletion of FGF21 and GDF15 does not result in any additional weight gain in response to high fat feeding but it does result in significantly greater hepatic steatosis and insulin resistance than that seen in GDF15 single knockout mice. Collectively the data suggest that overfeeding activates a stress response in the liver which is the major source of systemic rises in GDF15 and FGF21. These hormones then activate pathways which reduce this metabolic stress.

22 January 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JKJohn W. R. Kincaid
John W. R. Kincaid
DRDebra Rimmington
Debra Rimmington
JTJohn A. Tadross
John A. Tadross
ICIrene Cimino
Irene Cimino
IZIlona Zvetkova
Ilona Zvetkova
ACAnthony P. Coll
Anthony P. Coll
The hormone GDF15 is secreted in response to cellular stressors. Metformin elevates circulating levels of GDF15, an action important for the drug’s beneficial effects on body weight. Metformin can also inhibit mammalian respiratory complex I, leading to decreases in ATP:AMP ratio, activation of AMP Kinase (AMPK), and increased GDF15 production. We undertook studies using a range of mice with tissue-specific loss of Gdf15 (namely gut, liver and global deletion) to determine the relative contributions of two classical metformin target tissues, the gut and liver, to the elevation of GDF15 seen with metformin. In addition, we performed comparative studies with another pharmacological agent, the AMP kinase pan-activator, MK-8722. Deletion of Gdf15 from the intestinal epithelium significantly reduced the circulating GDF15 response to oral metformin, whereas deletion of Gdf15 from the liver had no effect. In contrast, deletion of Gdf15 from the liver, but not the gut, markedly reduced circulating GDF15 responses to MK-8722. Further, our data show that, while GDF15 restricts high-fat diet-induced weight gain, the intestinal production of GDF15 is not necessary for this effect. These findings add to the body of evidence implicating the intestinal epithelium in key aspects of the pharmacology of metformin action.

1 February 2023 in eLife
Verified
Journal Article
Open access
JMJake P Mann
Jake P Mann
XDXiaowen Duan
Xiaowen Duan
SPSatish Patel
Satish Patel
LTLuis Carlos Tábara
Luis Carlos Tábara
FSFabio Scurria
Fabio Scurria
DSDavid B Savage
David B Savage
Mitochondrial dysfunction has been reported in obesity and insulin resistance, but primary genetic mitochondrial dysfunction is generally not associated with these, arguing against a straightforward causal relationship. A rare exception, recently identified in humans, is a syndrome of lower body adipose loss, leptin-deficient severe upper body adipose overgrowth, and insulin resistance caused by the p.Arg707Trp mutation in MFN2, encoding mitofusin 2. How the resulting selective form of mitochondrial dysfunction leads to tissue- and adipose depot-specific growth abnormalities and systemic biochemical perturbation is unknown. To address this, Mfn2R707W/R707W knock-in mice were generated and phenotyped on chow and high fat diets. Electron microscopy revealed adipose-specific mitochondrial morphological abnormalities. Oxidative phosphorylation measured in isolated mitochondria was unperturbed, but the cellular integrated stress response was activated in adipose tissue. Fat mass and distribution, body weight, and systemic glucose and lipid metabolism were unchanged, however serum leptin and adiponectin concentrations, and their secretion from adipose explants were reduced. Pharmacological induction of the integrated stress response in wild-type adipocytes also reduced secretion of leptin and adiponectin, suggesting an explanation for the in vivo findings. These data suggest that the p.Arg707Trp MFN2 mutation selectively perturbs mitochondrial morphology and activates the integrated stress response in adipose tissue. In mice, this does not disrupt most adipocyte functions or systemic metabolism, whereas in humans it is associated with pathological adipose remodelling and metabolic disease. In both species, disproportionate effects on leptin secretion may relate to cell autonomous induction of the integrated stress response.

10 June 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SPSatish Patel
Satish Patel
AHAfreen Haider
Afreen Haider
AAAnna Alvarez-Guaita
Anna Alvarez-Guaita
GBGuillaume BIDAULT
Guillaume BIDAULT
JMJulia Sarah El-Sayed Moustafa
Julia Sarah El-Sayed Moustafa
DSDavid B. Savage
David B. Savage
Summary: Obesity in mice and humans is associated with elevated levels of at least two hormones responsive to cellular stress, namely GDF15 and FGF21. Over-expression of each of these is associated with weight loss and beneficial metabolic changes but where they are secreted from and what they are required for physiologically in the context of overfeeding remains unclear. Here we used tissue selective knockout mouse models to establish that, like FGF21, circulating GDF15 is primarily derived from the liver, rather than adipose tissue, muscle or macrophages in high fat fed mice. Combined whole body deletion of FGF21 and GDF15 does not result in any additional weight gain in high fat fed mice but is associated with significantly greater hepatic steatosis and insulin resistance. Collectively the data suggest that activation of the integrated stress response in hepatocytes is a major driver for GDF15 and FGF21 secretion in the context of overfeeding, and that they both act to alleviate this metabolic stress.

21 June 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
ACAnthony P Coll
Anthony P Coll
MCMichael Chen
Michael Chen
PTPranali Taskar
Pranali Taskar
DRDebra Rimmington
Debra Rimmington
SPSatish Patel
Satish Patel
SOStephen O’rahilly
Stephen O’rahilly
Summary: Metformin, the world’s most prescribed anti-diabetic drug, is also effective in preventing Type 2 diabetes in people at high risk, by lowering body weight, fat mass and circulating insulin levels through mechanisms that are incompletely understood. Recent observational studies reporting the association of metformin use and circulating levels of GDF15 led us to hypothesize that GDF15, which signals through a specific receptor complex in the hindbrain to reduce body weight, might mediate these effects. We measured GDF15 in people without diabetes from a randomized placebo-controlled trial of metformin. Over 18 months, participants allocated metformin lost significant weight and levels of GDF15 were persistently elevated compared to placebo. The change in plasma GDF15 in this study correlated positively with weight loss. In wild-type mice, oral metformin increased circulating GDF15 with GDF15 expression increasing predominantly in the distal intestine and the kidney. Metformin prevented weight gain in response to high fat diet in wild-type mice but not in mice lacking GDF15 or its receptor GFRAL. In obese, high fat-fed mice, the effects of metformin to reduce body weight were reversed by a GFRAL antagonist antibody. Metformin had effects on both energy intake and energy expenditure that required GDF15. The insulin sensitising effects of metformin determined by insulin tolerance were abolished in mice lacking GDF15. Metformin significantly reduced fasting glucose and insulin levels in wild type but not in mice lacking GDF15. In summary, metformin increases the circulating levels of GDF15, which appears to be necessary for many of its actions as a metabolic chemopreventive agent.